US2022127613A1PendingUtilityA1
Functionally-Modified Oligonucleotides And Subunits Thereof
Est. expiryNov 18, 2031(~5.3 yrs left)· nominal 20-yr term from priority
C12N 2310/314C12N 15/113C12N 15/1131A61P 31/12C07H 21/00C07D 413/02C12N 2310/3233C07F 9/65583C07F 9/65586C12N 2310/3513C07F 9/65616C12N 2310/346A61P 31/16C12N 2310/353C12N 2310/11A61P 31/04C12N 2310/351C07F 9/09C07F 9/65846
78
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
Claims
exact text as granted — not AI-modified1 . A compound having the structure of Formula (I):
or a salt or isomer thereof,
wherein:
n is an integer from 1 to 50;
G 5 is halogen, OH, alkoxy, OSO 2 (alkyl), OSO 2 (aryl), or
each B is an independently selected base pair moiety;
each Y is independently O or NR 10 ; optionally, R 10 and X8e are bonded together form a ring;
each W is independently S or O;
Z 5 is -(L 11 )-(R 15 ), -(L 11 )-(L 15 )-(R 16 ), or -(L 11 )-(L 12 )-(R 17 );
L 11 is selected from:
wherein L 13 is selected from:
L 12 is a linker cleaveable under biological conditions selected from:
a) —(C 1 -C 10 alkylene)-OC(O)O—CH 2 O—;
b) —C(O)—(C 1 -C 10 alkylene)-OC(O)O—CH 2 O—;
c) —C(O)—(CH═CH)—C(O)O—CH 2 O—;
d) —(C 1 -C 10 alkylene)-S—S—CH 2 CH 2 O—; or
e) —C(O)—(C 1 -C 10 alkylene)-S—S—CH 2 CH 2 O—;
L 15 is divalent radical selected from C 1 -C 30 alkylene, C 3 -C 8 cycloalkylene, C 6 -C 30 arylene, —(C 6 -C 30 arylene)-(C 1 -C 30 alkylene)-, —(C 1 -C 30 alkylene)-C(═O)—, —(C 2 -C 30 alkoxy)-C(═O)—, -(3-18 membered heteroalkylene)-C(═O)—, —(C 3 -C 8 cycloalkylene)-C(═O)—, —(C 3 -C 8 cycloalkylene)-(C 1 -C 30 alkylene)-C(═O)—, —(C 1 -C 30 alkylene) (C 3 -C 8 cycloalkylene)-C(═O)—, —(C 6 -C 30 arylene)-C(═O)—, —(C 6 -C 30 arylene)-(C 1 -C 30 alkylene)-C(═O)—, —(C 1 -C 30 alkylene)-(C 6 -C 30 arylene)-C(═O)—, —(C 1 -C 30 alkylene)-O—C(═O)—, —(C 3 -C 8 cycloalkylene)-O—C(═O)—, —(C 7 -C 30 arylene)-O—C(═O)—, —(C 6 -C 30 arylene)-(C 1 -C 30 alkylene)-O—C(═O)—, —(C 6 -C 30 arylene)-(C 1 -C 30 alkylene)-O—C(═O)—, —C(═O)OR 21 , or —P(═O)(R 22 ) 2 ;
R 12 is an electron pair, with the provision that if R 13 is C 1 -C 30 alkyl, then R 12 is an electron pair, an N-oxide, or C 1 -C 6 alkyl;
each R 10 and R 13 is independently selected from hydrogen, a cell-penetrating peptide, a natural or non-natural amino acid, guanidinyl, amidinyl, heterocyclyl, C 1 -C 30 alkyl, C 3 -C 8 cycloalkyl; C 6 -C 30 aryl, C 7 -C 30 aralkyl, C 1 -C 30 alkylcarbonyl, C 3 -C 8 cycloalkylcarbonyl, C 3 -C 8 cycloalkylalkylcarbonyl, C 6 -C 30 arylcarbonyl, C 7 -C 30 aralkylcarbonyl, C 1 -C 30 alkyloxycarbonyl, C 3 -C 8 cycloalkyloxycarbonyl, C 7 -C 30 aryloxycarbonyl, C 8 -C 30 aralkyloxycarbonyl, —C(═O)OR 21 , —C(═O)NHR 21 , or —P(═O)(R 22 ) 2 ;
R 15 is independently selected from a cell-penetrating peptide, a natural or non-natural amino acid, guanidinyl, amidinyl, heterocyclyl, C 1 -C 30 alkyl, C 3 -C 8 cycloalkyl; C 6 -C 30 aryl, C 7 -C 30 aralkyl, C 1 -C 30 alkylcarbonyl, C 3 -C 8 cycloalkylcarbonyl, C 3 -C 8 cycloalkylalkylcarbonyl, C 6 -C 30 arylcarbonyl, C 7 -C 30 aralkylcarbonyl, C 2 -C 30 alkyloxycarbonyl, C 3 -C 8 cycloalkyloxycarbonyl, C 7 -C 30 aryloxycarbonyl, C 8 -C 30 aralkyloxycarbonyl, 3-18 membered alkoxyalkylcarbonyl, —SO 2 R 21 , —C(═O)OR 21 , —P(═O)(OH) 2 or —P(═O)(R 22 ) 2 ;
R 16 is a solid support matrix suitable for solid phase synthesis of oligonucleotides;
R 17 is a drug, protein or toxin;
each R 21 is independently C 1 -C 30 alkyl, or a 3-18 membered alkoxyalkyl group;
each R 22 is independently an C 6 -C 12 aryloxy;
each R 23 is independently H or C 1 -C 6 alkyl; or optionally two R 23 groups join to form a 3- to 8-membered ring;
R 24 is a C 1 -C 6 alkylene;
Q is independently selected from X1, X2, X3, X4, X5, X6, X7, or X8;
each X is independently selected from X1, X2, X3, X4, X5, X6, X7, or X8 with the provision that at least one X is not X1;
wherein
X1 is N(CH 3 ) 2 ;
X2 is selected from:
a) —O-alkylene-CO 2 H;
b) —O-alkylene-CHN 4 ;
c) —N(R 1 )-alkylene-CO 2 H;
d) —N(R 1 )-alkylene-CHN 4 ;
e) -L1-CO-alkylene-CO 2 H;
f) -L1-CO-alkylene-CHN 4 ;
g) -L1-CO-alkenylene-CO 2 H;
h) -L1-CO-alkenylene-CHN 4 ;
i) -L1-CO-arylene-CO 2 H;
j) -L1-CO-arylene-CHN 4 ;
k) -L1-CONH-alkylene-CO 2 H;
l) -L1-CONH-alkylene-CHN 4 ;
m) -L1-CONH-arylene-CO 2 H;
n) -L1-CONH-arylene-CHN 4 ;
o) -L1-SO 2 -alkylene-CO 2 H;
p) -L1-SO 2 -alkylene-CHN 4 ;
q) -L1-SO 2 -arylene-CO 2 H;
r) -L1-SO 2 -arylene-CHN 4 ;
s) -L1-alkylene-CO 2 H;
t) -L1-alkylene-CHN 4 ;
u) -L1-arylene-CO 2 H;
v) -L1-arylene-CHN 4 ; and
w) a protected form of any of the above X2 groups;
X3 is selected from:
a) -L1-alkyl;
b) -L1-heterocyclyl;
c) —O-alkylene-CNH—NH 2 ;
d) —N(R 1 )-alkylene-CNH—NH 2 ;
e) -L1-CNH—NH 2 ;
f) -L1-alkylene-CNH—NH 2 ;
g) -L1-arylene-CNH—NH 2 ;
h) -L1-CO-alkylene-CNH—NH 2 ;
i) -L1-CO-alkenylene-CNH—NH 2 ;
j) -L1-CO-arylene-CNH—NH 2 ;
k) -L1-CONH-alkylene-CNH—NH 2 ;
l) -L1-CONH-arylene-CNH—NH 2 ;
m) -L1-SO 2 -alkylene-CNH—NH 2 ;
n) -L1-SO 2 -arylene-CNH—NH 2 ;
o) —O-alkylene-N(R 1 ) 2 ;
p) —N(R 1 )-alkylene-N(R 1 ) 2 ;
q) -L1-N(R 1 ) 2 ;
r) -L1-alkylene-N(R 1 ) 2 ;
s) -L1-arylene-N(R 1 ) 2 ;
t) -L1-CO-alkylene-N(R 1 ) 2 ;
u) -L1-CO-alkenylene-N(R 1 ) 2 ;
v) -L1-CO-arylene-N(R 1 ) 2 ;
w) -L1-CONH-alkylene-N(R 1 ) 2 ;
x) -L1-CONH-arylene-N(R 1 ) 2 ;
y) -L1-SO 2 -alkylene-N(R 1 ) 2 ;
z) —O-alkylene-N(R 2 ) 3 ;
aa) —N(R 1 )-alkylene-N(R 2 ) 3 ;
bb) -L1-N(R 2 ) 3 ;
cc) -L1-alkylene-N(R 2 ) 3 ;
dd) -L1-arylene-N(R 2 ) 3 ;
ee) -L1-CO-alkylene-N(R 2 ) 3 ;
ff) -L1-CO-alkenylene-N(R 2 ) 3 ;
gg) -L1-CO-arylene-N(R 2 ) 3 ;
hh) -L1-CONH-alkylene-N(R 2 ) 3 ;
ii) -L1-CONH-arylene-N(R 2 ) 3 ;
jj) -L1-SO 2 -alkylene-N(R 2 ) 3 ;
kk) —O-alkylene-heterocyclyl;
ll) —N(R 1 )-alkylene-heterocyclyl;
mm) -L1-alkylene-heterocyclyl;
nn) -L1-arylene-heterocyclyl;
oo) -L1-CO-alkylene-heterocyclyl;
pp) -L1-CO-alkenylene-heterocyclyl;
qq) -L1-CO-arylene-heterocyclyl;
rr) -L1-CONH-alkylene-heterocyclyl;
ss) -L1-CONH-arylene-heterocyclyl;
tt) -L1-SO 2 -alkylene-heterocyclyl;
uu) —O-alkylene-N(O)(R 2 ) 2 ;
vv) —N(R 1 )-alkylene-N(O)(R 2 ) 2 ;
ww) -L1-N(O)(R 2 ) 2 ;
xx) -L1-alkylene-N(O)(R 2 ) 2 ;
yy) -L1-arylene-N(O)(R 2 ) 2 ;
zz) -L1-CO-alkylene-N(O)(R 2 ) 2 ;
aaa) -L1-CO-alkenylene-N(O)(R 2 ) 23 ;
bbb) -L1-CO-arylene-N(O)(R 2 ) 2 ;
ccc) -L1-CONH-alkylene-N(O)(R 2 ) 2 ;
ddd) -L1-CONH-arylene-N(O)(R 2 ) 2 ;
eee) -L1-SO 2 -alkylene-N(O)(R 2 ) 2 ;
fff) —O-alkylene-NH—CNH—NH 2 ;
ggg) —N(R 1 )-alkylene-NH—CNH—NH 2 ;
hhh) -L1-NH—CNH—NH 2 ;
iii) -L1-alkylene-NH—CNH—NH 2 ;
jjj) -L1-arylene-NH—CNH—NH 2 ;
kkk) -L1-CO-alkylene-NH—CNH—NH 2 ;
lll) -L1-CO-alkenylene-NH—CNH—NH 2 ;
mmm) -L1-CO-arylene-NH—CNH—NH 2 ;
nnn) -L1-CONH-alkylene-NH—CNH—NH 2 ;
ooo) -L1-CONH-arylene-NH—CNH—NH 2 ;
ppp) -L1-SO 2 -alkylene-NH—CNH—NH 2 ;
qqq) -L1-SO 2 -arylene-NH—CNH—NH 2 ; and
rrr) a protected form of any of the above X3 groups;
with the provision that if X1 is present as N(CH 3 ) 2 , and X7 is present as piperidinyl, then X3 is not
X4 is selected from:
a) —O-alkylene-aryl;
b) —N(R 1 )-aryl;
—N(R 1 )-alkylene-aryl;
d) -L1-CO-alkylene-aryl;
e) -L1-CO-alkenylene-aryl;
f) -L1-CO-arylene-aryl;
g) -L1-CONH-alkylene-aryl;
h) -L1-CONH-arylene-aryl;
i) -L1-SO 2 -alkylene-aryl;
j) -L1-SO 2 -arylene-aryl;
k) -L1-alkylene-aryl;
l) -L1-arylene-aryl;
m) —N(R 1 )-alkylene-N(R 1 )-aryl;
n) —N(R 1 )-alkylene-N(R 1 )CO-aryl;
o) —N(R 1 )-alkylene-N(R 1 )SO 2 -aryl;
p) —N(R 1 )-alkylene-N(R 1 )CH 2 -aryl;
q) -L1-aryl;
r) -L1-CO-aryl;
s) -L1-SO 2 -aryl;
t) -L1-alkylene-P(aryl) 3 ;
u) -L1-CO-alkylene-P(aryl) 3 ;
v) -L1-SO 2 -alkylene-P(aryl) 3 ; and
w) a protected form of any of the above X4 groups;
X5 is selected from:
a) —O-alkylene-heteroaryl;
b) —N(R 1 )-alkylene-heteroaryl;
c) -L1-CO-alkylene-heteroaryl;
d) -L1-CO-alkenylene-heteroaryl;
e) -L1-CO-arylene-heteroaryl;
f) -L1-CONH-alkylene-heteroaryl;
g) -L1-CONH-arylene-heteroaryl;
h) -L1-SO 2 -alkylene-heteroaryl;
i) -L1-SO 2 -arylene-heteroaryl;
j) -L1-alkylene-heteroaryl;
k) -L1-arylene-heteroaryl;
l) —N(R 1 )-alkylene-N(R 1 )-hereroaryl;
m) —N(R 1 )-alkylene-N(R 1 )CO-hereroaryl;
n) —N(R 1 )-alkylene-N(R 1 )SO 2 -hereroaryl;
o) —N(R 1 )-alkylene-N(R 1 )CH 2 -hereroaryl;
p) -L1-heteroaryl; and
q) a protected form of any of the above X5 groups;
X6 is selected from:
a) —O-alkylene-(OCH 2 CH 2 ) m OH;
b) —O-alkylene-(OCH 2 CH 2 ) m OCH 3 ;
c) —N(R 1 )-alkylene-(OCH 2 CH 2 ) m OH;
d) —N(R 1 )-alkylene-(OCH 2 CH 2 ) m OCH 3 ;
e) —N(R 1 )-arylene-(OCH 2 CH 2 ) m OH;
f) —N(R 1 )-arylene-(OCH 2 CH 2 ) m OCH 3 ;
g) -L1-alkylene-(OCH 2 CH 2 ) m OH;
h) -L1-CO-alkylene-(OCH 2 CH 2 ) m OH;
i) -L1-CO-alkylene-(OCH 2 CH 2 ) m OCH 3 ;
j) -L1-SO 2 -alkylene-(OCH 2 CH 2 ) m OH;
k) -L1-SO 2 -alkylene-(OCH 2 CH 2 ) m OCH 3 ;
l) -L1-CO-arylene-(OCH 2 CH 2 ) m OH;
m) -L1-CO-arylene-(OCH 2 CH 2 ) m OCH 3 ;
n) -L1-SO 2 -arylene-(OCH 2 CH 2 ) m OH;
o) -L1-SO 2 -arylene-(OCH 2 CH 2 ) m OCH 3 ;
p) -L1-CO—(OCH 2 CH 2 ) m OH;
q) -L1-CO—(OCH 2 CH 2 ) m OCH 3 ;
r) —N(R 1 )-(dibenzo-18-crown-6);
s) an aza-crown ether; and
t) a protected form of any of the above X6 groups;
X7 is selected from:
a) -heterocyclyl;
b) —N(R 1 )(R 3 )
c) -L1-hydrogen;
d) -L1-alkyl;
e) -L1-CO-alkyl;
f) -L1-CONH-alkyl;
g) -L1-CON(alkyl)-alkyl;
h) -L1-SO 2 -alkyl; and
i) a protected form of any of the above X7 groups;
with the provision that if X1 is present as N(CH 3 ) 2 , and X3 is present as
then X7 is not piperdinyl;
X8 is selected from:
a) -L1-CA;
b) -L1-dCA;
c) -L1-COCH 2 (R 4 )
d) -L1-COCH(R 4 )NHCO 2 -alkyl;
e) —OR 5 , wherein R 5 and R 10 together form a ring;
f) a protected form of any of the above X8 groups;
each R 1 is independently hydrogen, alkyl, or a cell-penetrating peptide;
each R 2 is independently C 1 -C 12 alkyl or optionally when two R 2 are C 1 -C 12 alkyl, two R 2 are joined to form a heterocyclic ring;
each R 3 is independently C 2 -C 18 alkyl, alkenyl, or alkynyl;
each R 4 is independently hydrogen, alkyl, hydroxyalkyl, sulfhydrylalkyl, or arylalkyl;
each R 5 is independently C 1 -C 12 alkyl;
each R 6 is independently hydrogen or C 1 -C 12 alkyl;
L1 is selected from:
wherein
each Q 1 and Q 2 are each selected from a bond, —O— or —N(R 6 )—;
each E 1 is independently selected from optionally substituted aryl or optionally substituted heteroaryl;
each E 2 is independently an optionally substituted nitrogen containing heteroaryl;
each L 4 and L 5 are each independently a bond, optionally substituted C 1 -C 6 alkyl, or optionally substituted heteroalkyl; and
m, p, q, s, and t are each independently 1-4.
2 - 9 . (canceled)
10 . The compound of claim 1 , wherein Z 5 is -(L 11 )-(R 15 ); each Y is independently O, NH, or NR 10 ; each W is O; each R 1 is independently hydrogen or alkyl; each R 2 is independently C 1 -C 12 alkyl; and each X is independently selected from X1, X2, X3, X4, X5, X6, X7, or X8.
11 - 16 . (canceled)
17 . The compound of claim 1 , wherein R 13 is an optionally substituted triphenylmethyl group.
18 - 26 . (canceled)
27 . The compound of claim 10 , wherein G 5 is
28 . The compound of claim 27 , wherein each W is O and each Y is O.
29 - 48 . (canceled)
49 . The compound of claim 28 , wherein at least one X is selected from:
50 - 51 . (canceled)
52 . The compound of claim 28 , wherein at least one X is selected from -L1-heterocyclyl, and wherein L1 is selected from:
53 - 54 . (canceled)
55 . The compound of claim 28 , wherein at least one X is selected from:
56 - 57 . (canceled)
58 . The compound of claim 28 , wherein at least one X is selected from —N(R 1 )-alkylene-CNH—NH 2 , —N(R 1 )-alkylene-N(R 1 ) 2 , —N(R 1 )-alkylene-N(R 2 ) 3 , —N(R 1 )-alkylene-heterocyclyl, —N(R 1 )-alkylene-N(O)(R 2 ) 2 , and —N(R 1 )-alkylene-NH—CNH—NH 2 .
59 - 92 . (canceled)
93 . The compound of claim 28 , wherein at least one X is selected from —O-alkylene-aryl, —N(R 1 )-aryl, —N(R 1 )-alkylene-aryl, —N(R 1 )-alkylene-N(R 1 )-aryl, —N(R 1 )-alkylene-N(R 1 )CO-aryl, —N(R 1 )-alkylene-N(R 1 )SO 2 -aryl, and —N(R 1 )-alkylene-N(R 1 )CH 2 -aryl.
94 - 127 . (canceled)
128 . The compound of claim 28 , wherein at least one X is selected from —O-alkylene-heteroaryl, —N(R 1 )-alkylene-heteroaryl, —N(R 1 )-alkylene-N(R 1 )-heteroaryl, —N(R 1 )-alkylene-N(R 1 )CO-heteroaryl, —N(R 1 )-alkylene-N(R 1 )SO 2 -heteroaryl, and —N(R 1 )-alkylene-N(R 1 )CH 2 -heteroaryl.
129 - 134 . (canceled)
135 . The compound of claim 28 , wherein at least one X is selected from -L1-heteroaryl, -L1-alkylene-heteroaryl, -L1-arylene-heteroaryl, -L1-CO-alkylene-heteroaryl, -L1-CO-alkenylene-heteroaryl, -L1-CO-arylene-heteroaryl, -L1-CONH-alkylene-heteroaryl, -L1-CONH-arylene-heteroaryl, -L1-SO 2 -alkylene-heteroaryl, -L1-SO 2 -arylene-heteroaryl.
136 - 172 . (canceled)
173 . The compound of claim 28 , wherein at least one X is -L1-CO-alkyl.
174 - 175 . (canceled)
176 . The compound of claim 28 , wherein at least one X is X8.
177 - 229 . (canceled)
230 . The compound of claim 28 , wherein Z 5 is -(L 11 )-(R 15 ) wherein R 15 is selected from —C(═O)OCH 2 CH 2 OH, —C(═O)OCH 2 CH 2 OCH 2 CH 2 OH, or —C(═O)OCH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OH.
231 - 232 . (canceled)
233 . The compound of claim 230 , wherein Z 5 is
234 - 291 . (canceled)Join the waitlist — get patent alerts
Track US2022127613A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.